hTERT promoter regulated replication-selective adenovirus CNHK300 in treatment of hepatocellular carcinoma

National Medical Journal of China

Volumn 85, Issue 7, 2005, Pages 468-472

  Li, Yue Min ^a   Song, San Tai ^b   Jiang, Ze Fei ^b   Zhang, Qi ^b   Su, Chang Qing ^b   Xu, Jian Ming ^b   Qian, Yan Zhen ^b   Qian, Qi Jun ^b  

^a Clinical Cancer Centre   (China)

^b NONE

Author keywords

Gene therapy; Hepatocellular carcinoma; Telomerase

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; E1A PROTEIN; GREEN FLUORESCENT PROTEIN; ONYX 015; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ADENOVIRUS 5; ARTICLE; CALCULATION; CANCER CELL CULTURE; CELL ISOLATION; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; CYTOPLASM; EMBRYO; FIBROBLAST CULTURE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INOCULATION; KIDNEY CELL; LIVER CELL CARCINOMA; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; SURVIVAL RATE; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; WESTERN BLOTTING; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; CARCINOMA, HEPATOCELLULAR; CLONING, MOLECULAR; DNA-BINDING PROTEINS; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TELOMERASE; VIRUS REPLICATION;

EID: 14844296396     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Russell WC. Update on adenovirus and it's vectors. J Gen Virol, 2000,81:2573-2604.
2. Dominik Wodarz. Viruses as antitumor weapons: Defining conditions for tumor remission. Cancer Res, 2001, 61:3501-3507.
3. Kurihara T, Brough DE, Kovesdi I, et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest,2000,106:763-771.
4. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene, 2001,269:1-12.
5. Su CQ, Xue HB, Wang XH, et al. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting to the telomerase-positive cancer cells. J cancer Research and Clinical Oncology. J Cancer Res Clin Oncol, 2004,130:591-603.
6. Bischoff JR, Kirn DH, Williams A. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science, 1996,274:373-376.
7. Khuri F, Nemunaitis J, Ganly I. et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med, 2000, 6:879-885.
8. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer, 1997, 33:787-791.
9. Irving J, Wang Z, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther, 2004,11: 174-185.
10. Huang TG, Savontaus MJ, Shinozaki K, et al. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther, 2003,10: 1241-1247.
11. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res, 2003, 63: 3181-3188.
12. Rothmann T, Hengstermann A, Whitaker NJ. et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol, 1998, 72:9470-9478.
13. Ramachandra M, Rahman A, Zou A. et al. Reengineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol, 2001,19:1035-1041.